19 November 2021: Original Paper
Diagnostic Utility of Presepsin in Infections After Liver Transplantation: A Preliminary Study
Takahiro Yokose 1ABCDEF* , Masashi Takeuchi 1ABCDEF* , Hideaki Obara 1ACDEFG* , Masahiro Shinoda 2ADF , Hirofumi Kawakubo 1ADF , Minoru Kitago 1BCD , Hiroshi Yagi 1BCD , Yuta Abe 1BCD , Yohei Yamada 1BCD , Kentaro Matsubara 1BCD , Go Oshima 1BCD , Shutaro Hori 1BCD , Takumi Fujimura 1BCD , Ryo Takemura 3CD , Ryota Ishii 3CD , Tatsuo Kuroda 1A , Yuko Kitagawa 1AGDOI: 10.12659/AOT.933774
Ann Transplant 2021; 26:e933774
Table 1 Patient characteristics.
| Variables, (%) | Total (n=13) |
|---|---|
| Recipient age, years* | 44 (38–55) |
| Body mass index, kg/m* | 20.3 (19.2–24.0) |
| Sex, Male/Female | 4 (30.8) / 9 (69.2) |
| ASA-PS, 2 / 3 / 4 | 2 (15.4) / 7 (53.8) / 4 (30.8) |
| ECOG-PS, 0 / 1 / 2 / 3 | 1 (7.7) / 4 (30.8) / 5 (38.5) / 3 (23.1) |
| Primary disease | |
| Alcohol-related liver disease | 4 (30.8) |
| Primary biliary cholangitis | 3 (23.1) |
| Primary sclerosing cholangitis | 2 (15.4) |
| Autoimmune hepatitis | 2 (15.4) |
| Hepatopulmonary syndrome | 1 (7.7) |
| Unknown | 1 (7.7) |
| Child-Pugh score* | 12 (11–13) |
| MELD score* | 25 (18–32) |
| Creatinine clearance* | 68.1 (40.8–98.5) |
| Donor type | |
| Living / deceased | 7 (53.8) / 6 (46.2) |
| Donor age, years* | 44 (31–52) |
| ABO blood type | |
| Identical / Compatible / Incompatible | 9 (69.2) / 2 (15.4) / 2 (15.4) |
| Donor Liver | |
| Left lobe / Right lobe / Whole liver | 7 (53.8) / 1 (7.7) / 5 (38.5) |
| Intraoperative bleeding, ml* | 2760 (1415–5583) |
| Operation time, min* | 774 (708–913) |
| Bile duct reconstruction | |
| Hepaticocholedochostomy / Hepaticojejunostomy | 11 (84.6) / 2 (15.4) |
| Postoperative acute kidney injury | 9 (69.2) |
| Postoperative continuous renal replacement therapy | 4 (30.8) |
| * Median (25–75 percentiles). ASA – American Society of Anesthesiologists; PS – performance status; ECOG – Eastern Cooperative Oncology Group; MELD – model for end-stage liver disease. | |